Gergel Ivan P. 4
4 · NEKTAR THERAPEUTICS · Filed Oct 3, 2017
Insider Transaction Report
Form 4
Gergel Ivan P.
SVP & Chief Medical Officer
Transactions
- Exercise/Conversion
Common Stock
2017-10-02$11.04/sh+56,704$626,012→ 98,279 total - Sale
Common Stock
2017-09-29$24.04/sh−43,296$1,040,836→ 41,575 total - Exercise/Conversion
Common Stock
2017-09-29$11.04/sh+43,296$477,988→ 84,871 total - Sale
Common Stock
2017-10-02$24.21/sh−56,704$1,372,804→ 41,575 total - Exercise/Conversion
Stock Option
2017-09-29−43,296→ 370,456 totalExercise: $11.04Exp: 2022-05-18→ Common Stock (43,296 underlying) - Exercise/Conversion
Stock Option
2017-10-02−56,704→ 313,752 totalExercise: $11.04Exp: 2022-05-18→ Common Stock (56,704 underlying)
Footnotes (4)
- [F1]This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]This transaction was executed in multiple trades at prices ranging from $24.04 to $24.06. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.
- [F3]This transaction was executed in multiple trades at prices ranging from $24.04 to $24.46. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.
- [F4]The stock option pursuant to this transaction vests as follows: 25% of the shares subject to the option vested on May 19, 2015 and the remaining 75% of the shares vest in equal monthly installments over the three-year period thereafter based on the Reporting Person's continuous service to the issuer.